Company news

Editas Medicine, Inc. news in 2020

Editas Medicine, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors

December 16, 2020

Editas Medicine Announces Submission of IND Application for EDIT-301 with the FDA

December 8, 2020

Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

December 4, 2020

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

November 9, 2020

Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit

November 8, 2020

Editas Medicine Appoints Lisa A. Michaels, M.D., as Chief Medical Officer

November 8, 2020

Editas Medicine Announces Third Quarter 2020 Results and Update

November 4, 2020

Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update

October 28, 2020

Editas Medicine to Participate in Upcoming Investor Conference

September 30, 2020

Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference

September 10, 2020

Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease

August 23, 2020

Editas Medicine Regains Full Global Rights to Ocular Medicines

August 5, 2020

Editas Medicine Announces Second Quarter 2020 Results and Update

August 5, 2020

Editas Medicine Appoints Gad Berdugo as Chief Business Officer

July 26, 2020

Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update

July 22, 2020

Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing

July 6, 2020

Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares

June 25, 2020

Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease

June 11, 2020

Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies

May 14, 2020

Editas Medicine Announces First Quarter 2020 Results and Update

May 6, 2020

Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update

April 29, 2020

Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers

April 28, 2020

Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

March 3, 2020

Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update

February 25, 2020

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update

February 18, 2020

Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference

January 12, 2020

Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer

January 12, 2020

Editas Medicine Reports Inducement Grants to New Chief Financial Officer

January 9, 2020

Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth

January 8, 2020

Editas Medicine to Present at the 38th Annual J.P. Morgan Healthcare Conference

January 1, 2020

Calls in 2020

Decks in 2020